Merck pays Moderna $250m for joint development of skin cancer vaccine
Moderna’s mRNA vaccine is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Moderna’s mRNA vaccine is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma
Recurring global deadly disease outbreaks crippling economies
HT team October 5, 2022: More than 500 global health workers across WHO’s six regions are meeting in Armenia to reflect on lessons learnt from the response to multiple emergencies and draw plans to strengthen the body’s Emergency
CDC's response to the Pandemic was found to be woefully inadequate, says a review report
Rampant antibiotics resistance needs speedier regulatory approval for new drugs
HQ Team September 21, 2022: The age-old debate of “to have or not to have” vitamins persists, with some calling them essential supplements and others expensive placebos. Experts, nutritionists, and doctors are divided in their opinions on the